|Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D.||Chairman & CEO||480.75k||165.82k||1960|
|Mr. Jeffrey M. Yordon||COO & Pres of Athenex Pharmaceutical Division||693.45k||1.64k||1949|
|Dr. Rudolf Kwan M.D., M.B., B.S.||Chief Medical Officer||483.2k||N/A||1953|
|Dr. Simon C. Pedder Ph.D.||Chief Bus. & Strategy Officer of Proprietary Products||392.42k||N/A||1961|
|Dr. Allen Barnett||Co-Founder & Pres Emeritus||N/A||N/A||N/A|
|Mr. Steven J. Adams||Interim Chief Accounting Officer||N/A||N/A||1968|
|Ms. Teresa Brophy Bair||Gen. Counsel, Sr. VP of Admin. & Corp. Sec.||N/A||N/A||1971|
|Ms. Jacqueline Li||VP of Alliance Management & Corp. Devel.||N/A||N/A||N/A|
|Mr. John W. Matthei||VP of HR||N/A||N/A||N/A|
|Dr. Wing-Kai Chan||Deputy Chief Medical Officer of Orascovery & Src Kinase Platforms||N/A||N/A||N/A|
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and PT01 (Pegtomarginase), an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
Athenex, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 7. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 8; Compensation: 3.